Last reviewed · How we verify
NCT06822140: EVAMOS
Effect of Vagus Nerve Stimulation Via the Outer Ear on Motor and Cognitive Deficits After Ischemic Stroke
NA trial testing transcutaneous auricular vagus nerve stimulation in Ischemic Stroke in 144 participants. Not yet recruiting.
29 February 2028
Quick facts
| Lead sponsor | Rheinburg-Klinik |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 144 |
| Start date | 1 April 2025 |
| Primary completion | 29 February 2028 |
| Estimated completion | 30 April 2028 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- transcutaneous auricular vagus nerve stimulation
- sham-stimulation
Conditions studied
- Ischemic Stroke — all drugs for Ischemic Stroke →
- Motor Deficits — all drugs for Motor Deficits →
- Cognitive Impairment — all drugs for Cognitive Impairment →
- Vagus Nerve Stimulation — all drugs for Vagus Nerve Stimulation →
Sponsor
Rheinburg-Klinik
Who can join
18 and older, any sex, with Ischemic Stroke or Motor Deficits. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if transcutaneous auricular vagus nerve stimulation (taVNS) works to treat motor and neurocognitive deficits after ischemic stroke when applied within 30 days after onset of stroke. The main questions it aims to answer are: * Does tVNS improve motor deficits measured by the Fugl-Mayer assessment after ischemic stroke? * Does tVNS ameliorate stroke-related cognitive impairment? Researchers will compare tVNS to a placebo (sham stimulation, i.e. an electrode is fixed on the ear without applying electrical impulses ) to see if tVNS works to treat motor and cognitive deficits after stroke . Participants will: * Receive tVNS or sham stimulation for 30 minutes 5 days a week during 5 weeks after ischemic stroke * Receive smotor and cognitive training during the tVNS or sham stimulation * Will take part on a standardized stroke rehabilitation program during the 5 weeks in a rehabilitation clinic.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06822140
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of transcutaneous auricular vagus nerve stimulation
Trials testing the same drug.
- NCT07192757 — Improving Speech in Noise Perception for Individuals With Age-related Hearing Loss · NA · recruiting
- NCT07344402 — Optimization of taVNS Intervention Strategies for Refractory Constipation · NA · recruiting
- NCT06817161 — Benefit of Transcutaneous Auricular Vagus Nerve Stimulation in Improving Quality of Life in First Line Treatment of Ovar · Phase 3 · recruiting
- NCT07022171 — Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression · NA · recruiting
- NCT06975124 — taVNS Effects on Fear Ratings in Naturalistic Context · Phase 1 · recruiting
Other recruiting trials for Ischemic Stroke
Currently open trials in the same condition.
- NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
- NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
- NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
- NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
- NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06822140 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rheinburg-Klinik
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06822140.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing